专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

KR20180056778A FOXM1 유래 펩티드 및 이를 포함하는 백신 审中-公开
公开(公告)号：KR20180056778A
公开(公告)日：2018-05-29
申请号：KR20187012991
申请日：2016-10-06
申请人： ONCOTHERAPY SCIENCE INC
发明人： YAMASHITA SACHIKO , HIKICHI TETSURO
IPC分类号： C07K7/08 , A61K35/12 , A61K35/17 , A61K38/00 , A61K48/00 , C12N5/0783 , G01N33/68
CPC分类号： A61K35/12 , A61K35/17 , A61K38/00 , A61K48/00 , C07K7/06 , C12N5/10 , C12N15/09 , G01N33/15 , G01N33/50
摘要： 본발명은세포독성 T 세포를유도할수 있는 FOXM1 유래에피톱펩티드를제공한다. 본발명은더 나아가, 상기펩티드를코딩하는폴리뉴클레오티드, 상기펩티드를제시하는항원제시세포, 및상기펩티드를타겟하는세포독성 T 세포뿐만아니라, 항원제시세포또는 CTL의유도방법도제공한다. 본발명은또한유효성분으로서그들을포함하는조성물또는약학적조성물을제공한다. 더나아가, 본발명은본 발명의펩티드, 폴리뉴클레오티드, 항원제시세포, 세포독성 T 세포또는약학적조성물을사용하여암의치료및/또는예방방법, 및/또는이의수술후 재발을예방하는방법을제공한다. 암에대해면역반응을유도하는방법도또한제공한다.

2. 发明公开

KR20180055892A MPHOSPH1-유래 펩티드 및 이를 포함하는 백신 审中-公开
公开(公告)号：KR20180055892A
公开(公告)日：2018-05-25
申请号：KR20187012067
申请日：2016-10-06
申请人： ONCOTHERAPY SCIENCE INC
发明人： YAMASHITA SACHIKO , HIKICHI TETSURO
IPC分类号： C07K7/06 , A61K39/00 , A61K48/00 , A61P35/00 , C07K16/18 , C12N5/078 , C12N5/0783 , G01N33/50
CPC分类号： A61K35/15 , A61K35/17 , A61K39/00 , A61K48/00 , C07K7/06 , C07K16/28 , C12N1/00 , C12N15/09
摘要： 본발명은세포독성 T 세포를유도할수 있는 MPHOSPH1-유래에피톱펩티드를제공한다. 본발명은더 나아가, 상기펩티드를코딩하는폴리뉴클레오티드, 상기펩티드를제시하는항원제시세포, 및상기펩티드를타겟하는세포독성 T 세포뿐만아니라, 항원제시세포또는 CTL의유도방법도제공한다. 본발명은또한유효성분으로서그들을포함하는조성물또는약학적조성물을제공한다. 더나아가, 본발명은본 발명의펩티드, 폴리뉴클레오티드, 항원제시세포, 세포독성 T 세포또는약학적조성물을사용하여암의치료및/또는예방방법, 및/또는이의수술후 재발을예방하는방법을제공한다. 암에대해면역반응을유도하는방법도또한제공한다.

3. 发明专利

JP2007191485A Kdr peptide and vaccine containing the same 有权
标题翻译：含KDR肽和含有它的疫苗
公开(公告)号：JP2007191485A
公开(公告)日：2007-08-02
申请号：JP2007058127
申请日：2007-03-08
申请人： Oncotherapy Science Inc , オンコセラピー・サイエンス株式会社
发明人： TAWARA HIDEAKI , WADA SATOSHI , TSUNODA TAKUYA
IPC分类号： C07K7/06 , A61K38/00 , A61K39/00 , A61P3/10 , A61P9/00 , A61P9/10 , A61P17/06 , A61P19/02 , A61P27/02 , A61P29/00 , A61P35/00 , A61P35/04 , C07K14/705 , C07K14/71 , C12N5/06 , C12N15/12
CPC分类号： A61K39/0011 , A61K2039/5154 , A61K2039/5156 , A61K2039/5158 , C07K7/06 , C07K14/71
摘要： PROBLEM TO BE SOLVED: To provide a peptide targeting a VEGF (vascular endothelial growth factor) receptor 2 strongly expressing in an endothelial cell of tumor tissue and effective as a cancer vaccine and provide a medicine containing the peptide and useful for the treatment or prevention of tumor. SOLUTION: The invention provides a peptide or decapeptide composed of a specific amino acid sequence derived from a VEGF receptor 2, a peptide having an amino acid sequence derived from the above amino acid sequences by substitution or addition of one to several amino acids and having cytotoxic T cell inducing activity, and a vaccine containing the peptide as an active component. COPYRIGHT: (C)2007,JPO&INPIT
摘要翻译：待解决的问题：提供靶向VEGF（血管内皮生长因子）受体2的肽，其在肿瘤组织的内皮细胞中强烈表达，并且作为癌症疫苗有效并提供含有该肽并可用于治疗的药物或预防肿瘤。解决方案：本发明提供了由衍生自VEGF受体2的特异性氨基酸序列组成的肽或十肽，其具有通过取代或添加一至几个氨基酸而具有来源于上述氨基酸序列的氨基酸序列的肽并具有细胞毒性T细胞诱导活性，以及含有肽作为活性成分的疫苗。版权所有（C）2007，JPO＆INPIT

4. 发明申请

WO2018092755A1 MPHOSPH1 EPITOPE PEPTIDES FOR TH1 CELLS AND VACCINES CONTAINING THE SAME 审中-公开
公开(公告)号：WO2018092755A1
公开(公告)日：2018-05-24
申请号：PCT/JP2017/040889
申请日：2017-11-14
申请人： ONCOTHERAPY SCIENCE, INC.
发明人： NISHIMURA, Yasuharu , HIRAYAMA, Masatoshi , TSURUTA, Miki , YAMASHITA, Sachiko
IPC分类号： C12N15/09 , A61K31/7088 , A61K35/26 , A61K39/00 , A61P35/00 , C07K7/06 , C07K7/08 , C07K14/47 , C07K16/30 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/0783 , C12N5/0784 , C12N5/10
摘要： Isolated MPHOSPH1-derived epitope peptides having Th1 cell inducibility are disclosed herein. Such peptides can be recognized by MHC class II molecules and induce Th1 cells. In preferred embodiments, such a peptide of the present invention can promiscuously bind to MHC class II molecules and induce MPHOSPH1-specific CTLs in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors including, for example, bladder cancer and breast cancer.

5. 发明申请

WO2014010232A1 LY6K EPITOPE PEPTIDES FOR TH1 CELLS AND VACCINES CONTAINING THE SAME 审中-公开
标题翻译：用于TH1细胞的LY6K EPITOPE肽和含有它的疫苗
公开(公告)号：WO2014010232A1
公开(公告)日：2014-01-16
申请号：PCT/JP2013/004249
申请日：2013-07-09
申请人： ONCOTHERAPY SCIENCE, INC.
发明人： NISHIMURA, Yasuharu , TOMITA, Yusuke , OSAWA, Ryuji
IPC分类号： C07K14/47 , A61K38/00 , A61K39/00 , A61P35/00 , C07K16/44 , C12N5/0783 , C12N15/09
CPC分类号： C07K14/435 , A61K38/00 , A61K39/00 , A61K39/0011 , A61K2039/5154 , A61K2039/55566 , A61K2039/57 , A61K2039/70 , C07K14/4748 , C07K16/18 , C07K16/2833 , C12N5/0634
摘要： Isolated LY6K-derived epitope peptides having Th1 cell inducibility are disclosed herein. Such peptides can be recognized by MHC class II molecules and induce Th1 cells. In preferred embodiments, such a peptide of the present invention can be promiscuously bind to MHC class II molecules and induce LY6K-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors including, for example, bladder cancer, cervical cancer, cholangiocellular carcinoma, esophageal cancer, gastric cancer, non-small cell lung cancer (NSCLC), osteosarcoma, pancreatic cancer, soft tissue tumor and head-and-neck malignant tumor(HNMT).
摘要翻译：本文公开了具有Th1细胞诱导能力的分离的LY6K衍生的表位肽。这样的肽可被MHC II类分子识别并诱导Th1细胞。在优选的实施方案中，本发明的这种肽可以与MHC II类分子混合结合，并诱导除了Th1细胞之外的LY6K特异性细胞毒性T淋巴细胞（CTL）。因此，这样的肽适合用于增强受试者的免疫应答，并因此在癌症免疫治疗中尤其是用作癌症疫苗时使用。本文还公开了编码由这些肽诱导的上述肽，APC和Th1细胞中的任何一种的多核苷酸以及与其相关的诱导方法。包含任何上述组分作为活性成分的药物组合物可用于治疗和/或预防癌症或肿瘤，包括例如膀胱癌，宫颈癌，胆管细胞癌，食道癌，胃癌，非小细胞肺癌症（NSCLC），骨肉瘤，胰腺癌，软组织肿瘤和头颈恶性肿瘤（HNMT）。

6. 发明申请

WO2014010231A1 KIF20A EPITOPE PEPTIDES FOR TH1 CELLS AND VACCINES CONTAINING THE SAME 审中-公开
标题翻译：用于TH1细胞的KIF20A抗原肽和含有它的疫苗
公开(公告)号：WO2014010231A1
公开(公告)日：2014-01-16
申请号：PCT/JP2013/004248
申请日：2013-07-09
申请人： ONCOTHERAPY SCIENCE, INC.
发明人： NISHIMURA, Yasuharu , TOMITA, Yusuke , OSAWA, Ryuji
IPC分类号： C07K14/47 , A61K38/00 , A61K39/00 , A61P35/00 , C07K16/44 , C12N5/0783 , C12N15/09
CPC分类号： A61K39/0011 , A61K38/00 , A61K39/0008 , A61K2039/5154 , A61K2039/5158 , A61K2039/57 , A61K2039/572 , A61K2039/70 , C07K7/06 , C07K7/08 , C07K14/00 , C07K14/47 , C07K16/2833 , C07K16/30 , C12N5/0634 , C12N5/0636 , C12N5/0638 , C12N9/14 , C12N2501/2302 , C12N2501/2307 , C12N2501/998 , C12N2502/11 , C12N2502/1114 , C12N2510/00 , C12Y306/04
摘要： Isolated KIF20A-derived epitope peptides having Th1 cell inducibility are disclosed herein. Such peptides can be recognized by MHC class II molecules and induce Th1 cells. In preferred embodiments, such a peptide of the present invention can promiscuously bind to MHC class II molecules and induce KIF20A-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors including, for example, bladder cancer, breast cancer, cholangiocellular carcinoma, esophageal cancer, non-small cell lung cancer (NSCLC), pancreatic cancer, prostate cancer, renal carcinoma, small cell lung cancer (SCLC) and head-and-neck malignant tumor (HNMT).
摘要翻译：本文公开了具有Th1细胞诱导能力的分离的KIF20A衍生的表位肽。这样的肽可被MHC II类分子识别并诱导Th1细胞。在优选的实施方案中，本发明的这种肽可以与MHC II类分子混合结合并诱导除了Th1细胞之外的KIF20A特异性细胞毒性T淋巴细胞（CTL）。因此，这样的肽适合用于增强受试者的免疫应答，并因此在癌症免疫治疗中尤其是用作癌症疫苗时使用。本文还公开了编码由这些肽诱导的上述肽，APC和Th1细胞中的任何一种的多核苷酸以及与其相关的诱导方法。包含任何上述组分作为活性成分的药物组合物可用于治疗和/或预防癌症或肿瘤，包括例如膀胱癌，乳腺癌，胆管细胞癌，食管癌，非小细胞肺癌（NSCLC）），胰腺癌，前列腺癌，肾癌，小细胞肺癌（SCLC）和头颈恶性肿瘤（HNMT）。

7. 发明申请

WO2013109388A2 1,5-NAPHTHYRIDINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME 审中-公开
标题翻译：含有1,5-萘啶衍生物和含有其的咪唑类抑制剂
公开(公告)号：WO2013109388A2
公开(公告)日：2013-07-25
申请号：PCT/US2012/071434
申请日：2012-12-21
申请人： ONCOTHERAPY SCIENCE, INC.
发明人： MATSUO, Yo , HISADA, Shoji , NAKAMURA, Yusuke , AHMED, Feryan , WALKER, Joel R. , HUNTLEY, Raymond
IPC分类号： A61K31/4745 , C07D471/04
CPC分类号： A61K31/5377 , A61K31/4375 , A61K31/496 , A61K31/506 , C07D471/04
摘要： The present invention directs a compound represented by formula (I).
摘要翻译：本发明涉及由式（I）表示的化合物。

8. 发明申请

WO2013061594A1 TOPK PEPTIDES AND VACCINES INCLUDING THE SAME 审中-公开
标题翻译： TOPK PEPTIDES和疫苗，包括它们
公开(公告)号：WO2013061594A1
公开(公告)日：2013-05-02
申请号：PCT/JP2012/006853
申请日：2012-10-25
申请人： ONCOTHERAPY SCIENCE, INC.
发明人： NAKAMURA, Yusuke , TSUNODA, Takuya , OSAWA, Ryuji , YOSHIMURA, Sachiko , WATANABE, Tomohisa , NAKAYAMA, Gaku
IPC分类号： C07K7/06 , A61K38/00 , A61K48/00 , A61P35/00 , C07K16/18 , C12N5/10 , C12N15/09 , G01N33/574
CPC分类号： A61K39/0011 , A61K38/00 , A61K39/0005 , A61K2039/5154 , A61K2039/572 , C07K7/06 , C07K14/4748 , C07K16/18 , C07K16/40 , C07K2317/34 , C12N9/12 , C12N9/1205 , C12Y207/12002 , G01N33/505 , G01N33/574
摘要： Isolated epitope peptides derived from TOPK and immunogenic fragments thereof have an ability to induce cytotoxic T lymphocytes (CTLs) and thus are suitable for use in cancer immunotherapy, more particularly as cancer vaccines. The peptides of the present invention encompass both of peptides including a TOPK-derived amino acid sequence and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted and/or added, provided such modified versions have CTL inducibility. Further provided are polynucleotides encoding any of the aforementioned peptides as well as pharmaceutical compositions that include any of the aforementioned peptides or polynucleotides. The peptides, polynucleotides, and pharmaceutical compositions of this invention find particular utility in either or both of the treatment and prevention of cancers and tumors.
摘要翻译：衍生自TOPK的分离的表位肽及其免疫原性片段具有诱导细胞毒性T淋巴细胞（CTL）的能力，因此适用于癌症免疫治疗，特别是癌症疫苗。本发明的肽包括包括TOPK衍生的氨基酸序列和其修饰形式的两种肽，其中一个，两个或几个氨基酸被取代，缺失，插入和/或添加，只要这些修饰版本具有CTL 诱导性。还提供了编码任何前述肽的多核苷酸以及包括任何上述肽或多核苷酸的药物组合物。本发明的肽，多核苷酸和药物组合物在癌症和肿瘤的治疗和预防中的任一个或两者中都特别有用。

9. 发明申请

WO2011161960A1 C1ORF59 FOR TARGET GENES OF CANCER THERAPY AND DIAGNOSIS 审中-公开
标题翻译： C1ORF59针对目标癌症治疗和诊断基因
公开(公告)号：WO2011161960A1
公开(公告)日：2011-12-29
申请号：PCT/JP2011/003564
申请日：2011-06-22
申请人： ONCOTHERAPY SCIENCE, INC. , NAKAMURA, Yusuke , DAIGO, Yataro , TSUNODA, Takuya
发明人： NAKAMURA, Yusuke , DAIGO, Yataro , TSUNODA, Takuya
IPC分类号： C12N15/09 , C12N15/113 , G01N33/15 , G01N33/50
CPC分类号： G01N33/5011 , C12N15/113 , C12N15/1137 , C12N2310/14 , C12Q1/48 , C12Q2600/158 , C12Y201/01 , G01N33/57407 , G01N33/57411 , G01N33/57419 , G01N33/57423 , G01N2333/91011 , G01N2500/00
摘要： Objective methods for diagnosing a predisposition to developing cancer are described herein. In one embodiment, the diagnostic method involves determining an expression level of the C1orf59 gene, the PIWIL4 gene, or piRNA and correlating the determined level with a healthy, diseased or at-risk state. The present invention further provides methods of assessing or determining the prognosis of a patient with esophageal cancer. In one embodiment, the diagnostic method involves determining an expression level of the C1orf59 gene. The present invention further provides methods of screening for therapeutic substances useful in the treatment of a C1orf59-, and/or PIWIL4-associated disease, such as a cancer. The present invention further provides methods of treating or preventing a cancer expressing the C1orf59 gene and/or the PIWIL4 gene. The present invention also features products, including double-stranded molecules and vectors encoding thereof as well as to compositions including them.
摘要翻译：本文描述了用于诊断发展中的癌症倾向的客观方法。在一个实施方案中，诊断方法包括确定C1orf59基因，PIWIL4基因或piRNA的表达水平，并将确定的水平与健康的，患病的或处于危险的状态相关联。本发明还提供了评估或确定患有食管癌患者的预后的方法。在一个实施方案中，诊断方法涉及确定C1orf59基因的表达水平。本发明还提供筛选用于治疗C1orf59-和/或PIWIL4相关疾病如癌症的治疗物质的方法。本发明还提供了治疗或预防表达C1orf59基因和/或PIWIL4基因的癌症的方法。本发明还包括产物，包括双链分子和编码它们的载体以及包括它们的组合物。

10. 发明申请

WO2011122022A1 ECT2 PEPTIDES AND VACCINES INCLUDING THE SAME 审中-公开
标题翻译： ECT2肽和疫苗，包括它们
公开(公告)号：WO2011122022A1
公开(公告)日：2011-10-06
申请号：PCT/JP2011/001909
申请日：2011-03-30
申请人： ONCOTHERAPY SCIENCE, INC. , NAKAMURA, Yusuke , TSUNODA, Takuya , OHSAWA, Ryuji , YOSHIMURA, Sachiko , WATANABE, Tomohisa
发明人： NAKAMURA, Yusuke , TSUNODA, Takuya , OHSAWA, Ryuji , YOSHIMURA, Sachiko , WATANABE, Tomohisa
IPC分类号： C12N15/09
CPC分类号： C07K7/06 , A61K39/0011 , A61K2039/572
摘要： Isolated peptides derived from SEQ ID NO: 42 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines, are described herein. The inventive peptides encompass both the afore- mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite HLA binding and/or CTL inducibility of the original sequences. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and/or compositions that include or incorporate any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors, including, for example, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, esophageal cancer, NSCLC, lymphoma, pancreatic cancer, prostate cancer, renal carcinoma and SCLC.
摘要翻译：衍生自SEQ ID NO：42的分离的肽及其与HLA抗原结合并诱导细胞毒性T淋巴细胞（CTL）的片段，因此适用于癌症免疫治疗，特别是癌症疫苗的上下文中。本发明的肽包括上述氨基酸序列及其修饰形式，其中一个，两个或几个氨基酸被取代，缺失，插入或添加，只要这些修饰版本保留所需的HLA结合和/或CTL诱导性的原始序列。还提供了编码任何前述肽的核酸以及包括或掺入任何前述肽或核酸的药物，物质和/或组合物。本发明的肽，核酸，药物，物质和组合物在治疗癌症和肿瘤方面特别有用，包括例如膀胱癌，乳腺癌，子宫颈癌，胆管细胞癌，CML，结肠直肠癌，食管癌，NSCLC，淋巴瘤，胰腺癌，前列腺癌，肾癌和SCLC。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式